Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H25N3O3 |
Molecular Weight | 367.4415 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)NC1=CC2=C(CCC3=CC=CC=C3N2C(=O)CN(C)C)C=C1
InChI
InChIKey=KJAMZCVTJDTESW-UHFFFAOYSA-N
InChI=1S/C21H25N3O3/c1-4-27-21(26)22-17-12-11-16-10-9-15-7-5-6-8-18(15)24(19(16)13-17)20(25)14-23(2)3/h5-8,11-13H,4,9-10,14H2,1-3H3,(H,22,26)
Molecular Formula | C21H25N3O3 |
Molecular Weight | 367.4415 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8653799
7-day multiple-dose study period (50 mg tiracizine twice daily)
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:19:43 GMT 2023
by
admin
on
Sat Dec 16 17:19:43 GMT 2023
|
Record UNII |
9UUO2T61K7
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC01EB11
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
||
|
WHO-ATC |
C01EB11
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
||
|
NCI_THESAURUS |
C47793
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9UUO2T61K7
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
PRIMARY | |||
|
2679
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
PRIMARY | |||
|
CHEMBL1625260
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
PRIMARY | |||
|
C048166
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
PRIMARY | |||
|
6494
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
PRIMARY | |||
|
83275-56-3
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
PRIMARY | |||
|
DB13635
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
PRIMARY | |||
|
DTXSID5048714
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
PRIMARY | |||
|
TIRACIZINE
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
PRIMARY | |||
|
71264
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
PRIMARY | |||
|
C75137
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
PRIMARY | |||
|
SUB11114MIG
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
PRIMARY | |||
|
100000077265
Created by
admin on Sat Dec 16 17:19:43 GMT 2023 , Edited by admin on Sat Dec 16 17:19:43 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |